Finding myself with a lengthy layover at the Dublin Airport in Swords, Ireland, on my way to New York from BIO-Europe (and with a surprising lack of Guinness at the…
In July, 2025, GSK (UK) and Hengrui Pharmaceutical (China) executed a $12 billion license and option agreement valued at $12 billion, with $500 million paid upfront. The press release is…
Is Japan being ignored as a licensing partner in the biotech industry? Is China now getting all of the attention? Lacerta Bio explores this question.
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
Today, Derek Lowe points out that Shenzhen Chipscreen received CFDA approval for chid amide (Epidaza), the first drug to be completely discovered, developed and approved exclusively in China.…